| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $32,983,049 | 40 | 100 |
| Wei Lin | Chief Medical Officer | 0 | $0 | 2 | $185,532 | $-185,532 |
| Cislini Jeff | General Counsel | 0 | $0 | 9 | $1.7M | $-1.7M |
| Anders Jack | Chief Financial Officer | 0 | $0 | 9 | $2.93M | $-2.93M |
| Kelsey Stephen Michael | See Remarks | 0 | $0 | 7 | $7.74M | $-7.74M |
| Horn Margaret A | Chief Operating Officer | 0 | $0 | 5 | $8.39M | $-8.39M |
| GOLDSMITH MARK A | See Remarks | 0 | $0 | 8 | $12.04M | $-12.04M |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Over the last 12 months, insiders at Revolution Medicines, Inc. have bought $0 and sold $32.98M worth of Revolution Medicines, Inc. stock.
On average, over the past 5 years, insiders at Revolution Medicines, Inc. have bought $29.26M and sold $28.82M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,304,347 shares for transaction amount of $60M was made by Schroeder Thilo (director) on 2024‑12‑05.
| 2026-01-21 | Sale | Cislini Jeff | General Counsel | 908 0.0005% | $115.60 | $104,965 | -17.17% | |
| 2026-01-07 | Sale | Horn Margaret A | Chief Operating Officer | 75,000 0.048% | $100.56 | $7.54M | -3.69% | |
| 2026-01-07 | Sale | Anders Jack | Chief Financial Officer | 10,000 0.0062% | $98.00 | $980,000 | -3.69% | |
| 2025-12-16 | Sale | Kelsey Stephen Michael | See Remarks | 5,447 0.0028% | $76.82 | $418,423 | +25.10% | |
| 2025-12-16 | Sale | GOLDSMITH MARK A | See Remarks | 15,394 0.0079% | $76.82 | $1.18M | +25.10% | |
| 2025-12-16 | Sale | Horn Margaret A | Chief Operating Officer | 4,847 0.0025% | $76.82 | $372,333 | +25.10% | |
| 2025-12-16 | Sale | Anders Jack | Chief Financial Officer | 3,104 0.0016% | $77.09 | $239,289 | +25.10% | |
| 2025-12-16 | Sale | Cislini Jeff | General Counsel | 2,688 0.0014% | $76.82 | $206,484 | +25.10% | |
| 2025-11-25 | Sale | Anders Jack | Chief Financial Officer | 5,418 0.0029% | $74.00 | $400,932 | +14.73% | |
| 2025-11-25 | Sale | GOLDSMITH MARK A | See Remarks | 63,000 0.0345% | $75.08 | $4.73M | +14.73% | |
| 2025-11-18 | Sale | GOLDSMITH MARK A | See Remarks | 20,000 0.0103% | $70.38 | $1.41M | +14.17% | |
| 2025-11-18 | Sale | Cislini Jeff | General Counsel | 13,388 0.0069% | $70.14 | $939,008 | +14.17% | |
| 2025-11-12 | Sale | GOLDSMITH MARK A | See Remarks | 20,000 0.011% | $65.07 | $1.3M | +21.94% | |
| 2025-11-11 | Sale | Anders Jack | Chief Financial Officer | 10,000 0.0054% | $64.00 | $640,000 | +25.10% | |
| 2025-11-07 | Sale | GOLDSMITH MARK A | See Remarks | 30,000 0.0164% | $60.31 | $1.81M | +31.05% | |
| 2025-10-13 | Sale | Kelsey Stephen Michael | See Remarks | 25,000 0.0133% | $48.54 | $1.21M | +60.98% | |
| 2025-09-24 | Sale | Cislini Jeff | General Counsel | 1,799 0.001% | $44.26 | $79,624 | +78.16% | |
| 2025-09-16 | Sale | GOLDSMITH MARK A | See Remarks | 13,411 0.0074% | $45.82 | $614,558 | +70.34% | |
| 2025-09-16 | Sale | Kelsey Stephen Michael | See Remarks | 5,367 0.0029% | $45.82 | $245,942 | +70.34% | |
| 2025-09-16 | Sale | Horn Margaret A | Chief Operating Officer | 4,775 0.0026% | $45.82 | $218,814 | +70.34% |
| Kelsey Stephen Michael | See Remarks | 278600 0.1441% | $26.83M | 0 | 53 | |
| GOLDSMITH MARK A | See Remarks | 232469 0.1203% | $22.39M | 0 | 47 | |
| Horn Margaret A | Chief Operating Officer | 141053 0.073% | $13.58M | 0 | 34 | |
| Anders Jack | Chief Financial Officer | 108065 0.0559% | $10.41M | 0 | 28 | |
| Wei Lin | Chief Medical Officer | 88339 0.0457% | $8.51M | 0 | 3 | |
| Cislini Jeff | General Counsel | 46976 0.0243% | $4.52M | 0 | 28 | |
| TEPPER ROBERT I | 5104130 2.6403% | $491.58M | 0 | 1 | ||
| COLUMN GROUP III, LP | 10 percent owner | 2151026 1.1127% | $207.17M | 0 | 1 | |
| Schroeder Thilo | director | 2096612 1.0845% | $201.92M | 15 | 0 | +7.79% |
| Svennilson Peter | director | 1571963 0.8131% | $151.4M | 0 | 9 | |
| Flynn James E | 10 percent owner | 1297589 0.6712% | $124.97M | 1 | 0 | +14.18% |
| Kim Lorence H. | 60500 0.0313% | $5.83M | 1 | 0 | +5.12% | |
| Wang Xiaolin | See Remarks | 58813 0.0304% | $5.66M | 0 | 7 | |
| ANDERSON ELIZABETH M | director | 26990 0.014% | $2.6M | 0 | 3 | |
| Miller Vincent A. | director | 20133 0.0104% | $1.94M | 0 | 5 | |
| Patel Sushil | director | 19948 0.0103% | $1.92M | 0 | 3 | |
| Weber Barbara | director | 13065 0.0068% | $1.26M | 0 | 10 | |
| Third Rock Ventures II, L.P. | 10 percent owner | 0 0% | $0 | 0 | 4 | |
| Exter Neil | 0 0% | $0 | 0 | 3 |
$961,890,236 | 276 | 22.46% | $20.12B | |
$211,610,344 | 91 | 38.45% | $10.55B | |
$2,765,836 | 72 | 20.00% | $11.5B | |
$2,449,191,716 | 58 | 16.50% | $83.45B | |
$11,789,714 | 49 | 14.35% | $31.72B | |
$323,530,732 | 48 | 29.90% | $41.7B | |
$88,307,390 | 38 | -1.70% | $10.11B | |
$19,233,721 | 36 | 70.14% | $11.78B | |
$13,655,378 | 35 | 17.13% | $21.42B | |
$15,836,193 | 25 | 17.98% | $126.01B | |
$415,090,639 | 19 | -14.04% | $14.5B | |
Revolution Medicines, Inc. (RVMD) | $143,065,458 | 17 | 8.01% | $18.62B |
$152,272,932 | 16 | -10.78% | $19.36B | |
$627,701,115 | 15 | 145.68% | $11.14B | |
$284,820 | 10 | 45.67% | $13.06B | |
$948,235 | 8 | 15.56% | $9.38B | |
$40,276,273 | 4 | 34.57% | $18.93B | |
$36,900,000 | 3 | -9.12% | $10.99B | |
$999,989 | 1 | 262.16% | $16.5B |
| Increased Positions | 202 | +58.55% | 20M | +10.72% |
| Decreased Positions | 148 | -42.9% | 14M | -7.71% |
| New Positions | 81 | New | 6M | New |
| Sold Out Positions | 51 | Sold Out | 3M | Sold Out |
| Total Postitions | 399 | +15.65% | 194M | +3.01% |
| Vanguard Group Inc | $1.24M | 8.12% | 15.66M | -98,597 | -0.63% | 2025-09-30 |
| Farallon Capital Management Llc | $1.16M | 7.58% | 14.63M | +300,000 | +2.09% | 2025-09-30 |
| Janus Henderson Group Plc | $897,355.00 | 5.88% | 11.36M | +765,327 | +7.23% | 2025-09-30 |
| Wellington Management Group Llp | $775,458.00 | 5.09% | 9.81M | -446,302 | -4.35% | 2025-09-30 |
| Baker Bros. Advisors Lp | $747,162.00 | 4.9% | 9.46M | +90,385 | +0.96% | 2025-09-30 |
| Fmr Llc | $742,921.00 | 4.87% | 9.4M | +1M | +12.93% | 2025-09-30 |
| Blackrock, Inc. | $658,059.00 | 4.32% | 8.33M | -333,635 | -3.85% | 2025-09-30 |
| Nextech Invest, Ltd. | $600,638.00 | 3.94% | 7.6M | 0 | 0% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $491,764.00 | 3.23% | 6.22M | +130,000 | +2.13% | 2025-09-30 |
| Bellevue Group Ag | $440,445.00 | 2.89% | 5.57M | +994,538 | +21.72% | 2025-09-30 |